The presbyopia debate

Article

During the "Controversies in Cataract and Refractive Surgery" symposium, Dr Jack Holladay and Dr Theo Seiler debated the relative merits of presbyopia treatments.

During the “Controversies in Cataract and Refractive Surgery” symposium, Dr Jack Holladay and Dr Theo Seiler debated the relative merits of presbyopia treatments.

Dr Holladay argued that the ACI7000 corneal inlay (Acufocus, Inc.), which utilizes the pinhole effect to reduce the pupil size to 1.6 mm, improves the depth of field without impacting the cornea, and cited the initial 41 Acufocus implantations in Turkey; two years later, patients have 20/16 vision at near and distance, and the operating surgeon is satisfied with the results.

Dr Seiler countered by discussing the cosmetic and low light issues some patients have had with the Acufocus. He noted that we assume that what we know about the multifocality or asphericity of IOLs also holds true for the cornea. He mentioned several advantages of the aspheric hyperprolate cornea but observed that this is not a bilateral solution; he dismissed bifocal refractive treatments as there is limited prospective data, they are irreversible, and dissatisfaction is high. Monovision, he concluded, is currently the only clinically accepted approach.

 

To read OTE's full news coverage of the XXVI congress of the European Society of Cataract & Refractive Surgery, please click here.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.